Paper Details

  1. Home
  2. Paper Details

Effect of Dextromethorphan-Quinidine on Agitation in Patients With Alzheimer Disease Dementia: A Randomized Clinical Trial.

Author: AgroninMarc, CummingsJeffrey L, DavisCharles S, De La GandaraJose E, LyketsosConstantine G, MintzerJacobo E, NguyenUyen, PeskindElaine R, PorsteinssonAnton P, ScharreDouglas W, ShinPaul, SiffertJoão, TariotPierre N

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Dextromethorphan hydrobromide-quinidine sulfate demonstrated clinically relevant efficacy for agitation in patients with probable Alzheimer disease and was generally well tolerated.
Paper Details　
Original Abstract of the Article :
IMPORTANCE: Agitation is common among patients with Alzheimer disease; safe, effective treatments are lacking. OBJECTIVE: To assess the efficacy, safety, and tolerability of dextromethorphan hydrobromide-quinidine sulfate for Alzheimer disease-related agitation. DESIGN, SETTING, AND PARTICIPANTS: ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1001/jama.2015.10214

データ提供：米国国立医学図書館（NLM）

A New Approach to Managing Agitation in Alzheimer's Disease

This research investigates the efficacy and safety of a combination therapy, dextromethorphan-quinidine, for managing agitation in patients with Alzheimer's disease. The authors conducted a phase 2 randomized, double-blind, placebo-controlled trial, evaluating the effects of this medication on agitation levels in patients with probable Alzheimer's disease and significant agitation. The findings suggest that dextromethorphan-quinidine demonstrates clinically relevant efficacy in reducing agitation, offering a potential therapeutic option for managing this challenging symptom in Alzheimer's patients.

A Promising New Treatment Option

The study's findings provide a glimmer of hope for managing agitation in Alzheimer's patients, a symptom that can significantly impact quality of life and caregiver burden. The authors' observation of a clinically relevant reduction in agitation with dextromethorphan-quinidine warrants further investigation. This research could lead to improved symptom management and potentially enhanced quality of life for individuals living with Alzheimer's disease.

The Need for Further Research

The study's promising results highlight the need for larger-scale, well-designed clinical trials to confirm the efficacy and safety of dextromethorphan-quinidine for agitation treatment in Alzheimer's disease. These studies should be conducted to establish a robust evidence base for this potential therapeutic option and to explore its long-term effects and potential interactions with other medications. This research could lead to improved symptom management and potentially enhanced quality of life for individuals living with Alzheimer's disease.

Dr.Camel's Conclusion

This research is like finding a cool oasis in the desert of Alzheimer's disease. Agitation can be a challenging symptom, making life difficult for patients and caregivers. This study suggests that dextromethorphan-quinidine, like a refreshing spring of water, could offer relief from the discomfort of agitation. While more research is needed, this study provides a promising starting point for finding better ways to manage this challenging symptom.
Date :
  1. Date Completed 2015-10-01
  2. Date Revised 2022-04-09
Further Info :

Pubmed ID

26393847

DOI: Digital Object Identifier

10.1001/jama.2015.10214

Related Literature

Article Analysis
・Effects of dextromethorphan and quinidine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.